Stephens initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $13 price target The firm views the antibody-drug conjugate or ADC, space as “a highly promising technology” and notes that the company is nearing a pivotal event with the readout of their first-in-human, preliminary Phase 1 dose escalation study for a basket of solid tumors treated with lead asset PYX-201.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.